Sanford C. Bernstein Raises BioMarin Pharmaceutical Price Target to $94

The biotechnology company's stock receives an 'outperform' rating from the brokerage firm.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Sanford C. Bernstein has raised its price target for BioMarin Pharmaceutical (NASDAQ:BMRN) from $90 to $94, maintaining an 'outperform' rating on the biotechnology company's stock. The report notes that several other research firms have also recently weighed in on BioMarin, with ratings ranging from 'buy' to 'sell'.

Why it matters

BioMarin Pharmaceutical is a leading biopharmaceutical company focused on developing and commercializing therapies for rare genetic and metabolic diseases. The company's stock price and analyst coverage are closely watched by investors as indicators of the business's performance and future growth potential.

The details

In its report, Sanford C. Bernstein cited BioMarin's strong pipeline of enzyme replacement therapies, small molecule pharmacological chaperones, and gene therapy technologies as reasons for the increased price target. The brokerage firm maintains an 'outperform' rating on the stock, while other analysts have issued a range of ratings from 'buy' to 'sell'.

The price target increase was issued on Wednesday morning.

The players